Dr. Tripathi stated: "Alpha-synuclein is genetically tied to PD and accumulation of aSyn as intraneuronal aggregates in Lewy bodies and neurites is the neuropathological hallmark in PD patients. Our work demonstrated that pharmacological modulation of RXR targets alpha-synuclein clearance and counters proteotoxicity. Martin E. Sanders, M.D., Chief Executive Officer of Io Therapeutics, stated: "IRX4204 is a phase II clinical-stage compound invented by Vidyasagar Vuligonda, Ph.D., Chief Science Officer of Io Therapeutics, and Roshantha Chandraratna, Ph.D., co-founder of the company. More information about Io Therapeutics, Inc. and its product development programs is available at www.io-therapeutics.com . Io Therapeutics undertakes no obligation to update any forward-looking statements.